InvestAce Capital
@investace.capital.1462
Mumbai
4+ Years of experience
SEBI Registration INH000017736
Trade Ideas
105
Opinions
228
Followers
195
Expertise
Quantitative
Growth
Technical
Index Strategies
Market Commentary
Futures & Options
Technical Analysis
Trade Facts
Total Trades
0
Missed Trades
0
Profit Trades
0
0%Accuracy
Ask me Anything
Got a question? Ask me and I will answer it. Stay curious, stay hungry!
Posts
shared an insight ⚡️ 15 hours ago
Blue Dart announces 9% to 12% price increase
Blue Dart Express Limited
BLUEDART
will increase prices across its domestic portfolio by 9% to 12% from January 1, 2027.
The increase will vary according to the product and customer shipping profile. Customers signing up between October 1 and December 31, 2026, will be exempt from the upcoming increase.
Blue Dart said the revision is intended to offset higher labour and utility costs while supporting continued investment in its delivery network and technology.
The company reported Q1 FY27 consolidated revenue of ₹1,657.7 crore and net profit of ₹88.5 crore. EBITDA increased 33.5% year-on-year to ₹261.2 crore.
What I’m watching: The effect of the price increase on shipment volumes, revenue growth and operating margins from January 2027.
Stance: Tracking whether higher pricing offsets the increase in operating costs without materially affecting volumes.
Disclosure: This post is for educational purposes only and is not investment advice or a buy/sell recommendation. Disclose any holding or interest before publishing. shared an insight ⚡️ 19 hours ago
Aurobindo Pharma launches Adquey in US market
Aurobindo Pharma Limited
AUROPHARMA
has launched Adquey ointment in the US through its subsidiary Acrotech Biopharma.
The launch marks Acrotech’s entry into the US dermatology market. Aurobindo has also established a dedicated dermatology business unit to support the new product and build the segment.
The launch adds another therapeutic area to the company’s US portfolio. However, the financial impact will depend on prescription volumes, market adoption and the competitive environment.
What I’m watching: Initial sales contribution from Adquey, further dermatology launches and the company’s US product pipeline.
Stance: Tracking execution and commercial uptake following the US launch.
Disclosure: This post is for educational purposes only and is not investment advice or a buy/sell recommendation. Disclose any holding or interest before publishing. shared an insight ⚡️ 30th Sep
BSE replaces Wipro in Nifty 50 from September 30
BSE Limited
BSE
enters the Nifty 50 on September 30, replacing Wipro Limited following the index’s semi-annual review.
The change is based on the companies’ six-month average free-float market capitalisation. BSE’s average was reported at ₹1,40,879 crore, compared with ₹55,930 crore for Wipro. Wipro moves to the Nifty Next 50.
Index-tracking funds will adjust their holdings to reflect the revised index composition. This may affect trading activity around the effective date, but index inclusion does not directly change a company’s revenue, profit or cash flow.
What I’m watching: Trading volumes around the rebalancing and how both stocks perform after the index change takes effect.
Disclosure: This post is for educational purposes only and is not investment advice or a buy/sell recommendation. Disclose any holding or interest before publishing.FAQ's
What are the top stock recommendations by InvestAce Capital?
InvestAce Capital regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include BLUEDART, AUROPHARMA and BSE. Explore InvestAce Capital's complete list of posts and trade views on their StockGro profile.
How can I follow InvestAce Capital's latest investment insights?
You can follow InvestAce Capital's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.
What is InvestAce Capital's investment strategy?
InvestAce Capital follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.
How long has InvestAce Capital been a SEBI-registered Research Analyst (RA)?
InvestAce Capital has been a SEBI-registered Research Analyst and have 4+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.
Where can I see InvestAce Capital's past performance and stock picks?
You can check InvestAce Capital's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.
How can I contact InvestAce Capital for stock market advice?
For stock market guidance from InvestAce Capital, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.
What is InvestAce Capital's track record in predicting market movements?
InvestAce Capital has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.
What is the SEBI Registration number for InvestAce Capital?
InvestAce Capital is a SEBI-registered Research Analyst with the SEBI Registration INH000017736. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.
Be Financially Free with StockGro